Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ANIK's Cash-to-Debt is ranked higher than
97% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ANIK' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.5  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
ANIK's Equity-to-Asset is ranked higher than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANIK: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
ANIK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.77 Max: 0.94
Current: 0.93
0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
97% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s Interest Coverage Range Over the Past 10 Years
Min: 38.66  Med: 256.75 Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 26.48
Beneish M-Score: -2.68
WACC vs ROIC
8.13%
32.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 43.23
ANIK's Operating Margin % is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ANIK: 43.23 )
Ranked among companies with meaningful Operating Margin % only.
ANIK' s Operating Margin % Range Over the Past 10 Years
Min: 11.81  Med: 24.6 Max: 58.19
Current: 43.23
11.81
58.19
Net Margin % 28.23
ANIK's Net Margin % is ranked higher than
94% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ANIK: 28.23 )
Ranked among companies with meaningful Net Margin % only.
ANIK' s Net Margin % Range Over the Past 10 Years
Min: 7.77  Med: 18.03 Max: 36.29
Current: 28.23
7.77
36.29
ROE % 13.67
ANIK's ROE % is ranked higher than
90% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ANIK: 13.67 )
Ranked among companies with meaningful ROE % only.
ANIK' s ROE % Range Over the Past 10 Years
Min: 5.16  Med: 11.78 Max: 24.43
Current: 13.67
5.16
24.43
ROA % 12.66
ANIK's ROA % is ranked higher than
94% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ANIK: 12.66 )
Ranked among companies with meaningful ROA % only.
ANIK' s ROA % Range Over the Past 10 Years
Min: 3.27  Med: 8.37 Max: 21.97
Current: 12.66
3.27
21.97
ROC (Joel Greenblatt) % 56.59
ANIK's ROC (Joel Greenblatt) % is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ANIK: 56.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANIK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.35  Med: 40.48 Max: 110.18
Current: 56.59
13.35
110.18
3-Year Revenue Growth Rate 10.50
ANIK's 3-Year Revenue Growth Rate is ranked higher than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ANIK: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANIK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.4  Med: 7.5 Max: 26.7
Current: 10.5
-4.4
26.7
3-Year EBITDA Growth Rate 12.60
ANIK's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ANIK: 12.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANIK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.4  Med: 19.35 Max: 91.7
Current: 12.6
-64.4
91.7
3-Year EPS without NRI Growth Rate 15.60
ANIK's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ANIK: 15.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANIK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.2  Med: 20.15 Max: 72.4
Current: 15.6
-66.2
72.4
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANIK's 30-Y Financials

Financials (Next Earnings Date: 2018-02-15)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ANIK Guru Trades in Q4 2016

Paul Tudor Jones 17,069 sh (+33.03%)
Jim Simons 166,800 sh (-19.69%)
Ken Fisher 59,234 sh (-36.79%)
Joel Greenblatt 42,279 sh (-46.68%)
» More
Q1 2017

ANIK Guru Trades in Q1 2017

Columbia Wanger 170,229 sh (New)
Jim Simons 253,100 sh (+51.74%)
Paul Tudor Jones 25,275 sh (+48.08%)
Ken Fisher 70,153 sh (+18.43%)
Joel Greenblatt 22,664 sh (-46.39%)
» More
Q2 2017

ANIK Guru Trades in Q2 2017

Columbia Wanger 275,624 sh (+61.91%)
Joel Greenblatt 33,826 sh (+49.25%)
Ken Fisher 80,904 sh (+15.33%)
Jim Simons 144,900 sh (-42.75%)
Paul Tudor Jones 13,919 sh (-44.93%)
» More
Q3 2017

ANIK Guru Trades in Q3 2017

Chuck Royce 132 sh (New)
Paul Tudor Jones 19,042 sh (+36.81%)
Ken Fisher 105,716 sh (+30.67%)
Joel Greenblatt 42,927 sh (+26.91%)
Jim Simons 114,700 sh (-20.84%)
Columbia Wanger 175,710 sh (-36.25%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Add 30.67%$45.71 - $58.21 $ 54.825%105,716
Joel Greenblatt 2017-09-30 Add 26.91%0.01%$45.71 - $58.21 $ 54.825%42,927
Ken Fisher 2017-06-30 Add 15.33%$43.04 - $49.68 $ 54.8219%80,904
Joel Greenblatt 2017-06-30 Add 49.25%0.01%$43.04 - $49.68 $ 54.8219%33,826
Ken Fisher 2017-03-31 Add 18.43%$41.72 - $52.23 $ 54.8215%70,153
Joel Greenblatt 2017-03-31 Reduce -46.39%0.01%$41.72 - $52.23 $ 54.8215%22,664
Ken Fisher 2016-12-31 Reduce -36.79%$41.44 - $50.02 $ 54.8219%59,234
Joel Greenblatt 2016-12-31 Reduce -46.68%0.02%$41.44 - $50.02 $ 54.8219%42,279
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3841
Compare:NAS:AKBA, ROCO:4162, NAS:ABEO, NAS:RVNC, XPAR:GNFT, NAS:BYSI, TSE:4592, NAS:RETA, NAS:ITCI, HKSE:06826, NYSE:MYOV, TSE:2931, HKSE:01681, NAS:CRSP, XKRX:003000, SZSE:300497, SZSE:300583, ROCO:4105, OSTO:RECI B, XMCE:PHM » details
Traded in other countries:AKP.Germany,
Headquarter Location:USA
Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Top Ranked Articles about Anika Therapeutics Inc

6 Stocks Young Warren Buffett Would Buy in 2017 Technology and health care companies offer strong value potential
Six technology and health care companies made both the Undervalued Predictable Screener and the Buffett-Munger Screener as of May 4: Anika Therapeutics Inc. (NASDAQ:ANIK), NIC Inc. (NASDAQ:EGOV), Express Scripts Holding Co. (NASDAQ:ESRX), F5 Networks Inc. (NASDAQ:FFIV), CGI Group Inc. (NYSE:GIB) and Novo Nordisk A/S (NYSE:NVO). As these companies offer good growth and value potential, gurus are buying shares in these companies. Read more...
6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 A deeper look at the value screeners and FZM scores
As discussed in previous articles, the GuruFocus value screeners can identify strong value opportunities for short-term and long-term investing. The following six companies made multiple value screeners as of Mar. 29: Wipro Ltd. (NYSE:WIT), The Cheesecake Factory Inc. (NASDAQ:CAKE), Casey’s General Stores Inc. (NASDAQ:CASY), Anika Therapeutics Inc. (NASDAQ:ANIK), F5 Networks Inc. (NASDAQ:FFIV) and Copart Inc. (NASDAQ:CPRT). These six companies offer strong value potential for second-quarter 2017. Read more...
Steven Romick Spots Next Area of Investment Interest: Health Care Romick has third of portfolio in cash, awaiting opportunities
At the $33.1 billion FPA Crescent Fund, widely followed stock manager Steven Romick (Trades, Portfolio) puts avoiding risk first, but he also embraces volatile markets to make steely buys of plummeting equities. Read more...

Ratios

vs
industry
vs
history
PE Ratio 25.75
ANIK's PE Ratio is ranked higher than
57% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. ANIK: 25.75 )
Ranked among companies with meaningful PE Ratio only.
ANIK' s PE Ratio Range Over the Past 10 Years
Min: 8.57  Med: 20.08 Max: 46.32
Current: 25.75
8.57
46.32
Forward PE Ratio 29.67
ANIK's Forward PE Ratio is ranked lower than
75% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. ANIK: 29.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.75
ANIK's PE Ratio without NRI is ranked higher than
58% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. ANIK: 25.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
ANIK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.57  Med: 20.08 Max: 46.32
Current: 25.75
8.57
46.32
Price-to-Owner-Earnings 28.94
ANIK's Price-to-Owner-Earnings is ranked higher than
59% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. ANIK: 28.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ANIK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.32  Med: 28.11 Max: 470.43
Current: 28.94
12.32
470.43
PB Ratio 3.17
ANIK's PB Ratio is ranked higher than
56% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ANIK: 3.17 )
Ranked among companies with meaningful PB Ratio only.
ANIK' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 2.43 Max: 4.63
Current: 3.17
0.58
4.63
PS Ratio 7.32
ANIK's PS Ratio is ranked higher than
60% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ANIK: 7.32 )
Ranked among companies with meaningful PS Ratio only.
ANIK' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 4.35 Max: 9.17
Current: 7.32
1
9.17
Price-to-Free-Cash-Flow 26.37
ANIK's Price-to-Free-Cash-Flow is ranked higher than
56% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. ANIK: 26.37 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ANIK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.43  Med: 20.41 Max: 214.24
Current: 26.37
10.43
214.24
Price-to-Operating-Cash-Flow 21.03
ANIK's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. ANIK: 21.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANIK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.92  Med: 19 Max: 954.44
Current: 21.03
8.92
954.44
EV-to-EBIT 13.36
ANIK's EV-to-EBIT is ranked higher than
68% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ANIK: 13.36 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.7 Max: 37.9
Current: 13.36
1.8
37.9
EV-to-EBITDA 12.32
ANIK's EV-to-EBITDA is ranked higher than
68% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ANIK: 12.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 9.3 Max: 34
Current: 12.32
1.4
34
EV-to-Revenue 5.79
ANIK's EV-to-Revenue is ranked higher than
67% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ANIK: 5.79 )
Ranked among companies with meaningful EV-to-Revenue only.
ANIK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 3.3 Max: 7.5
Current: 5.79
0.2
7.5
PEG Ratio 1.02
ANIK's PEG Ratio is ranked higher than
68% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. ANIK: 1.02 )
Ranked among companies with meaningful PEG Ratio only.
ANIK' s PEG Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.67 Max: 32.24
Current: 1.02
0.29
32.24
Shiller PE Ratio 42.76
ANIK's Shiller PE Ratio is ranked lower than
53% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. ANIK: 42.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANIK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.29  Med: 39.87 Max: 113.22
Current: 42.76
14.29
113.22
Current Ratio 17.00
ANIK's Current Ratio is ranked higher than
88% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ANIK: 17.00 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s Current Ratio Range Over the Past 10 Years
Min: 2.84  Med: 7.21 Max: 23.7
Current: 17
2.84
23.7
Quick Ratio 15.27
ANIK's Quick Ratio is ranked higher than
86% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ANIK: 15.27 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 5.56 Max: 21.67
Current: 15.27
1.21
21.67
Days Inventory 245.37
ANIK's Days Inventory is ranked lower than
78% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. ANIK: 245.37 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s Days Inventory Range Over the Past 10 Years
Min: 98.12  Med: 152.44 Max: 245.37
Current: 245.37
98.12
245.37
Days Sales Outstanding 77.05
ANIK's Days Sales Outstanding is ranked lower than
71% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ANIK: 77.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.27  Med: 94.23 Max: 109.78
Current: 77.05
55.27
109.78
Days Payable 72.33
ANIK's Days Payable is ranked higher than
64% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. ANIK: 72.33 )
Ranked among companies with meaningful Days Payable only.
ANIK' s Days Payable Range Over the Past 10 Years
Min: 20.94  Med: 62.17 Max: 169.68
Current: 72.33
20.94
169.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
ANIK's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ANIK: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANIK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.7  Med: -2.7 Max: -0.2
Current: -0.8
-44.7
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.05
ANIK's Price-to-Net-Cash is ranked higher than
52% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ANIK: 6.05 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ANIK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.48  Med: 6.96 Max: 79.94
Current: 6.05
0.48
79.94
Price-to-Net-Current-Asset-Value 4.49
ANIK's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ANIK: 4.49 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ANIK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.34  Med: 4.34 Max: 40.16
Current: 4.49
0.34
40.16
Price-to-Tangible-Book 3.43
ANIK's Price-to-Tangible-Book is ranked higher than
62% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ANIK: 3.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANIK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.29  Med: 2.68 Max: 13.3
Current: 3.43
0.29
13.3
Price-to-Intrinsic-Value-Projected-FCF 1.51
ANIK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. ANIK: 1.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ANIK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 1.82 Max: 20.72
Current: 1.51
0.54
20.72
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.90
ANIK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 27 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. ANIK: 0.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ANIK' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.7  Med: 0.83 Max: 1.59
Current: 0.9
0.7
1.59
Price-to-Median-PS-Value 1.68
ANIK's Price-to-Median-PS-Value is ranked lower than
80% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ANIK: 1.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANIK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.92 Max: 2.19
Current: 1.68
0.11
2.19
Price-to-Peter-Lynch-Fair-Value 1.63
ANIK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
63% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. ANIK: 1.63 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ANIK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.85 Max: 5.53
Current: 1.63
0.37
5.53
Price-to-Graham-Number 1.98
ANIK's Price-to-Graham-Number is ranked higher than
63% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. ANIK: 1.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ANIK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.49  Med: 1.73 Max: 7.69
Current: 1.98
0.49
7.69
Earnings Yield (Greenblatt) % 7.50
ANIK's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ANIK: 7.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANIK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 9.3 Max: 56.4
Current: 7.5
2.6
56.4
Forward Rate of Return (Yacktman) % 19.03
ANIK's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. ANIK: 19.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ANIK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.3  Med: 21.7 Max: 54.5
Current: 19.03
-10.3
54.5

More Statistics

Revenue (TTM) (Mil) $112.76
EPS (TTM) $ 2.13
Beta0.96
Short Percentage of Float10.46%
52-Week Range $41.64 - 60.29
Shares Outstanding (Mil)14.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 112 119 123
EPS ($) 1.97 1.84 1.85
EPS without NRI ($) 1.97 1.84 1.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}